Immuron
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Immuron is a biotechnology company based in Melbourne, Australia.[1] In 2008, the company changed its name to Immuron Limited,[2] having previously operated as Anadis Limited.[3][4]
Immuron is primarily focused on antigen-primed as well as dairy-derived health products. Its proprietary technologies allow a rapid development for polyclonal antibody and other proteins-based solutions to a range of important diseases.[citation needed]. The company specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea (TD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market.[5]
External links
References
- ^ "Anadis". Australian Stock Exchange. 5 June 2007.[permanent dead link]
- ^ "About Us". immuron1. Retrieved 7 May 2022.
- ^ "Immuron Limited - ABN, ACN, Business names, Former names". www.aubiz.net. Retrieved 7 May 2022.
- ^ "IMMURON LIMITED - Australia Company". australia-corp.com. Retrieved 7 May 2022.
- ^ Canada, Asia Pacific Foundation of. "Valeo Pharma, Baralex Sign Distribution Agreement with Australia's Anadis Ltd". Asia Pacific Foundation of Canada. Retrieved 18 September 2017.
 | This biotechnology article is a stub. You can help Wikipedia by expanding it. |
 | This pharmacy-related article is a stub. You can help Wikipedia by expanding it. |